Foundry Partners, LLC Cytom X Therapeutics, Inc. Transaction History

Foundry Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 22, 2019	SELL	$9.5 - $19.16 $378,689 - $763,755	-39,862 Closed	0 $0
Q3 2018 Oct 17, 2018	SELL	$18.04 - $26.41 $1,118 - $1,637	-62 Reduced 0.16%	39,862 $737,000
Q2 2018 Jul 19, 2018	SELL	$21.38 - $29.68 $55,117 - $76,515	-2,578 Reduced 6.07%	39,924 $913,000
Q1 2018 May 16, 2018	SELL	$21.76 - $34.22 $2,132 - $3,353	-98 Reduced 0.23%	42,502 $1.21 Million
Q4 2017 Jan 25, 2018	SELL	$19.0 - $23.09 $639,825 - $777,555	-33,675 Reduced 44.15%	42,600 $899,000
Q3 2017 Oct 31, 2017	BUY	$13.53 - $18.17 $1.03 Million - $1.39 Million	76,275	76,275 $1.39 Million

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.